Corporate Overview

Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors.

Our lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of our proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. We believe that our preliminary Phase 1/2 data from our ongoing clinical trial provide us with clinical proof of concept for our HER2 Boltbody ISAC approach.

Bolt is also advancing additional Boltbody ISAC product candidates targeting CEA and PD-L1.


May 12, 2022

Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business HighlightsRead More

April 7, 2022

Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare ConferenceRead More

March 30, 2022

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business HighlightsRead More

View All News Releases


April 14, 2022 at 3:45 PM EDT

21st Annual Needham Virtual Healthcare Conference Read More

April 8 - April 13, 2022

American Association of Cancer Research (AACR) Annual Meeting 2022 Read More

February 16, 2022 at 2:00 PM PST

2022 SVB Leerink Global Healthcare Conference Read More

View All Upcoming Events